__NOTOC__<unk>  (developmental codes VT-464 and, formerly, INO-464) is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer. It is a nonsteroidal CYP17A1 inhibitor and works by inhibiting the production of androgens and estrogens in the body. As of July 2017,<unk>  is in phase II clinical trials for both prostate cancer and breast cancer. In January 2016, it was designated fast-track status by the United States Food and Drug Administration for prostate cancer. In April 2017,<unk>  received fast-track designation for breast cancer as well. __TOC__
Seviteronel
Vibegron
Clinatec
Telotristat ethyl
Crofelemer
Titermax
Palifermin
Tebentafusp